Rani Therapeutics scored $53 million in financing to take its oral pill designed to replace injectable drug delivery for chronic disease treatment into clinical trials.
The UK Government has announced plans to increase prescription charges by 20p, or 2.3%, to a record £8.80, effective 1 April.
AstraZeneca and MSD’s Lynparza is a step closer to being cleared in Europe as maintenance therapy for some patients with ovarian cancer.
Medical device company Carewave Medical is looking to raise $1 million to support its wearable pain relief technology, according to an SEC filing.
Senseonics Holdings Inc has announced that people with diabetes using the Eversense® brand Continuous Glucose Monitoring Systems, in EMEA markets now have the option to invite others to remotely view their real-time glucose readings and alerts from anywhere.
Samsung’s latest phones, the Galaxy S9 and S9+, will incorporate a new digital health app that will track users' blood pressure and stress level while helping researchers collect data. Seoul-based Samsung Electronics teamed up with the University of California San Fransisco to develop the research app, called My BP Lab.
Cognoa has gained regulatory recognition for its machine learning software as a class II diagnostic medical device for autism — meaning the digital health startup is now positioned to submit an application for full FDA clearance.
Orthotaxy’s Technology Will Be Leveraged to Develop Cost-Effective, Time-Efficient, User-Friendly Offering in a Broad Range of Orthopaedics Procedures.
Johns Hopkins researchers have invented a new class of immunotherapeutic agents that are more effective at harnessing the power of the immune system to fight cancer. Their approach results in significant inhibition of tumor growth, even against cancers which do not respond to existing immunotherapies used in the clinic. In collaboration with Insilico Medicine, a Baltimore-based leader in artificial intelligence for drug discovery, the team reports their results this week in Nature Communications.
Company to move forward with novel therapies for migraine and Parkinson’s disease
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.